Promotion of Cellular and Humoral Immunity against Foot-and-Mouth Disease Virus by Immunization with Virus-Like Particles Encapsulated in Monophosphoryl Lipid A and Liposomes
- 주제(키워드) foot-and-mouth disease , virus-like particles , vaccine , liposome , TLR4 agonist , immunogenicity
- 주제(기타) Immunology
- 주제(기타) Medicine, Research & Experimental
- 설명문(일반) [Kim, Woo Sik; Zhi, Yong; Byun, Eui-Baek; Seo, Ho Seong] Korea Atom Energy Res Inst, Res Div Radiat Sci, Jeongeup 56212, South Korea; [Zhi, Yong; Seo, Ho Seong] Univ Sci & Technol, Dept Radiat Sci, Daejeon 34057, South Korea; [Guo, Huichen] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Natl Foot & Mouth Dis Reference Lab, Lanzhou 730000, Peoples R China; [Lim, Jae Hyang] Ewha Womans Univ, Dept Microbiol, Coll Med, Seoul 03760, South Korea; [Lim, Jae Hyang] Ewha Womans Univ, Med Ctr, Ewha Educ & Res Ctr Infect, Seoul 03760, South Korea
- 등재 SCIE, SCOPUS
- OA유형 Green Published, gold
- 발행기관 MDPI
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000175130
- 본문언어 영어
- Published As http://dx.doi.org/10.3390/vaccines8040633
- PubMed https://pubmed.ncbi.nlm.nih.gov/33142799
초록/요약
Virus-like particles (VLPs) have emerged as promising vaccine candidates against foot-and-mouth disease (FMD). However, such vaccines provide a relatively low level of protection against FMD virus (FMDV) because of their poor immunogenicity. Therefore, it is necessary to design effective vaccine strategies that induce more potent immunogenicity. In order to investigate the means to improve FMD VLP vaccine (VLPFMDV) immunogenicity, we encapsulated VLPs (MPL/DDA-VLPFMDV) with cationic liposomes based on dimethyldioctadecylammonium bromide (DDA) and/or monophosphoryl lipid A (MPL, TLR4 agonist) as adjuvants. Unlike inactivated whole-cell vaccines, VLPFMDV were successfully encapsulated in this MPL/DDA system. We found that MPL/DDA-VLPFMDV could induce strong cell-mediated immune responses by inducing not only VLP-specific IFN-gamma(+)CD4(+) (Th1), IL-17A(+)CD4(+) (Th17), and IFN-gamma(+)CD8(+) (activated CD8 response) T cells, but also the development of VLP-specific multifunctional CD4(+) and CD8(+) memory T cells co-expressing IFN-gamma, TNF-alpha, and IL-2. In addition, the MPL/DDA-VLPFMDV vaccine markedly induced VLP-specific antibody titers; in particular, the vaccine induced greater Th1-predominant IgG responses than VLPFMDV only and DDA-VLPFMDV. These results are expected to provide important clues for the development of an effective VLPFMDV that can induce cellular and humoral immune responses, and address the limitations seen in current VLP vaccines for various diseases.
more